<SEC-DOCUMENT>0001157523-21-000021.txt : 20210107
<SEC-HEADER>0001157523-21-000021.hdr.sgml : 20210107
<ACCEPTANCE-DATETIME>20210107085656
ACCESSION NUMBER:		0001157523-21-000021
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20210106
FILED AS OF DATE:		20210107
DATE AS OF CHANGE:		20210107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ImmunoPrecise Antibodies Ltd.
		CENTRAL INDEX KEY:			0001715925
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39530
		FILM NUMBER:		21513079

	BUSINESS ADDRESS:	
		STREET 1:		880 - 580 HORNBY STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C3B6
		BUSINESS PHONE:		6048060626

	MAIL ADDRESS:	
		STREET 1:		880 - 580 HORNBY STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C3B6
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a52357867.htm
<DESCRIPTION>IMMUNOPRECISE ANTIBODIES LTD. 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: business wire
         Document created using EDGARfilings PROfile 7.2.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: center;">
      <div style="font-family: 'Times New Roman',serif; font-size: 1pt;">&#160;<br>
      </div>
      <div style="font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">UNITED STATES</div>
      <div style="font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
      <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</div>
      <div style="font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">FORM 6-K</div>
      <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</div>
      <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
      <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</div>
      <div style="font-family: 'Times New Roman',Times,serif;">For the month of January 2021</div>
      <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="font-family: 'Times New Roman',Times,serif;">Commission File Number: <font style="font-weight: bold;">001-39530</font></div>
      <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">ImmunoPrecise Antibodies Ltd.</div>
      <div style="font-family: 'Times New Roman',Times,serif;">(Translation of registrant&#8217;s name into English)</div>
      <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8</div>
      <div style="font-family: 'Times New Roman',Times,serif;">(Address of principal executive office)</div>
      <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="font-family: 'Times New Roman',Times,serif; text-align: left;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
      <div><br>
      </div>
      <div style="font-family: 'Times New Roman',Times,serif; text-align: left;">Form 20-F&#160; <font style="font-family: 'Segoe UI Symbol',sans-serif;">&#9744;</font> Form 40-F&#160; <font style="font-family: 'Segoe UI Symbol',sans-serif;">&#9746;</font></div>
      <div style="font-family: 'Times New Roman',Times,serif; text-align: left;">&#160;</div>
      <div style="font-family: 'Times New Roman',Times,serif; text-align: left;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <font style="font-family: 'Segoe UI Symbol',sans-serif;">&#9744;</font></div>
      <div style="font-family: 'Times New Roman',Times,serif; text-align: left;">&#160;</div>
      <div style="font-family: 'Times New Roman',Times,serif; text-align: left;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <font style="font-family: 'Segoe UI Symbol',sans-serif;">&#9744;</font>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"></div>
      </div>
      <div>
        <div style="font-family: 'Times New Roman',serif; font-size: 1pt;">&#160;</div>
      </div>
      <div style="font-weight: bold;">EXHIBIT INDEX</div>
      <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; color: rgb(0, 0, 0);" id="zfda4c3d0442343c88fbd07bf0b9a10b6">

          <tr>
            <td style="width: 10%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-weight: bold;">Exhibit No.</div>
            </td>
            <td style="width: 1.54%; vertical-align: bottom;">
              <div>&#160;</div>
            </td>
            <td style="width: 88%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-weight: bold;">Description</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top;">
              <div><a href="a52357867_ex991.htm">99.1</a></div>
            </td>
            <td style="width: 1.54%; vertical-align: bottom;">
              <div>&#160;</div>
            </td>
            <td style="width: 88%; vertical-align: bottom;">
              <div><a href="a52357867_ex991.htm">Press Release dated January 06, 2021.</a></div>
            </td>
          </tr>

      </table>
      <div style="margin-top: 6pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
      </div>
      <div style="margin-top: 6pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">SIGNATURE</div>
      <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</div>
      <div style="font-family: 'Times New Roman',Times,serif; text-align: left; text-indent: 16pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
        undersigned, thereunto duly authorized.</div>
      <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; color: rgb(0, 0, 0);" id="z310d9f3b1f0b43618913cb5c4bc218a4">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="font-weight: bold;">IMMUNOPRECISE ANTIBODIES LTD.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top;">
              <div>&#160;</div>
            </td>
            <td style="width: 47%; vertical-align: top;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>Date: January 06, 2021</div>
            </td>
            <td style="width: 3%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-style: italic;">/s/ Lisa Helbling</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top;">
              <div>&#160;</div>
            </td>
            <td style="width: 47%; vertical-align: top;">
              <div>Lisa Helbling</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top;">
              <div>&#160;</div>
            </td>
            <td style="width: 47%; vertical-align: top;">
              <div>Chief Financial Officer</div>
            </td>
          </tr>

      </table>
      <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a52357867_ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: business wire
         Document created using EDGARfilings PROfile 7.2.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div>
    <div class="bw-release">
      <h1> <b>ImmunoPrecise Antibodies Announces Grant of Stock Options</b> </h1>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p>VICTORIA, British Columbia--(BUSINESS WIRE)--January 6, 2021--IMMUNOPRECISE ANTIBODIES LTD. (&#8220;<b>IPA</b>&#8221; or the &#8220;<b>Company</b>&#8221;) (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery, today announced that its
            board of directors has approved the grant of 25,000 stock options (the &#8220;<b>Options</b>&#8221;) under its stock option plan to acquire up to an aggregate of 25,000 common shares in the capital of IPA (&#8220;<b>Common Shares</b>&#8221;). Each of the five
            non-executive directors of IPA has been granted 5,000 Options. </p>
          <p> Each Option is exercisable for a period of five years from the date of grant at an exercise price of C$20.30 per Common Share. One quarter of the Options granted to each director will vest every three months from the date of grant. </p>
          <p> <b>About ImmunoPrecise Antibodies Ltd.</b> </p>
          <p> IPA is a global technology platform company with end-to-end solutions empowering companies to discover and develop therapies against any disease. The Company&#8217;s experience and cutting-edge technologies enable unparalleled support of its
            partners in their quest to bring innovative treatments to the clinic. IPA&#8217;s full-service capabilities dramatically reduce the time required for, and the inherent risk associated with, conventional multi-vendor product development. For further
            information, visit www.immunoprecise.com or contact solutions@immunoprecise.com. </p>
          <p> <b>Forward-Looking Information and Statements </b> </p>
          <p> This news release contains forward-looking statements within the meaning of applicable United States securities laws and Canadian securities laws. Forward-looking statements are often identified by the use of words such as "plans", "expects"
            or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might"
            or "will" be taken, occur or be achieved. Forward-looking information contained in this news release include, but are not limited to, statements regarding the vesting schedule of the Options. In respect of the forward-looking information
            contained herein, the Company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. </p>
          <p> Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or
            achievements expressed or implied by the forward-looking information. Actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, those risks discussed in the
            Company&#8217;s Annual Information Form dated November 16, 2020 (which may be viewed on the Company&#8217;s profile at www.sedar.com) and the Company&#8217;s Form 40-F dated December 28, 2020 (which may be viewed on the Company&#8217;s profile at www.sec.gov). Should
            one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the
            forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on the forward-looking information contained in this news release. </p>
          <p> The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. The Company does not assume any obligation to update or revise any forward-looking
            statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. </p>
          <p> Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. </p>
        </div>
        <div class="bw-release-contact">
          <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
          <p> Fr&#233;d&#233;ric Chabot <br>
            1-438-863-7071 <br>
            frederick@contactfinancial.com </p>
        </div>
      </div>
    </div>
    <font style="font-weight: bold;"> </font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
